{"id":949161,"date":"2026-04-06T11:46:10","date_gmt":"2026-04-06T15:46:10","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/biodesix-announces-aacr-2026-posters-and-presentations-highlighting-novel-diagnostic-test-discovery-pipeline-development\/"},"modified":"2026-04-06T11:46:10","modified_gmt":"2026-04-06T15:46:10","slug":"biodesix-announces-aacr-2026-posters-and-presentations-highlighting-novel-diagnostic-test-discovery-pipeline-development","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/biodesix-announces-aacr-2026-posters-and-presentations-highlighting-novel-diagnostic-test-discovery-pipeline-development\/","title":{"rendered":"Biodesix Announces AACR 2026 Posters and Presentations, Highlighting Novel Diagnostic Test Discovery & Pipeline Development"},"content":{"rendered":"

\nIncludes novel proteomic and genomic approaches to oncology therapeutic selection, response monitoring, and Molecular Residual Disease (MRD) testing
\n<\/h2>\n
\n

LOUISVILLE, Colo., April 06, 2026 (GLOBE NEWSWIRE) — Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that the company will present seven abstracts, including two oral sessions, at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA, from April 17 – 22, 2026. The presentations demonstrate Biodesix capabilities in blood- and tissue-based testing and monitoring across a range of applications.<\/p>\n

\u201cBiodesix expertise in test discovery and development, regulatory, reimbursement, and commercialization provides an exceptional level of service for our partners across a range of applications. The AACR presentations showcase basic research through clinical applications and pre-validated assays available for biopharma and life science partners, as well as advancements in our pipeline efforts. The data are reinforced by more than a decade of experience supporting the clinical development and commercialization of new diagnostics and therapeutics,\u201d said Gary Pestano, PhD, Chief Scientific Officer, Biodesix.<\/p>\n

\u201cThe depth of experience and success across the Biodesix team, spanning real-world clinical care and cutting-edge research, will be on full display at this year\u2019s AACR. It is especially exciting to see our genomic and proteomic technologies, combined with advanced data informatics, translating into meaningful clinical impact in our pipeline product concepts while also fueling strong momentum in our Development Services business as we move into 2026,\u201d said Scott Hutton, CEO, Biodesix.<\/p>\n

\n
\n Tumor & Immune Profiling Expertise<\/u>
\n <\/strong>\n <\/p>\n

Biodesix oral and poster presentations highlight diverse technology platforms, rapid turn-around times for our clinical tests, and extensive capabilities in immune and tumor profiling using mass spectrometry, Bio-Rad Droplet Digital PCR\u2122, and Thermo Fisher Ion AmpliSeq<\/a>\u2122 platforms. In addition, Biodesix has validated a new clinical myeloid panel on the Thermo Fisher Ion Torrent\u2122 Genexus\u2122 System<\/a>. The platform supports an automated clinical next-generation sequencing (NGS) workflow and can deliver sequencing results in as little as 24 hours.<\/p>\n

Sunday, April 19 | 3PM\u20135PM PST\u200b | Oral Presentation | Room 17, Mezzanine Level, Convention Center
\u200bTitle<\/strong>: Real-world analysis of NSCLC* variant-level frequencies from liquid biopsy testing in diverse U.S. populations\u200b<\/p>\n

Monday, April 20 | 2PM\u20135PM PST | Poster Section 41
Poster:<\/strong> 3743. ddPLEX EGFR\/KRAS\/BRAF: A highly multiplexed droplet digital PCR\u2122 (ddPCR\u2122) panel for ultra-sensitive NSCLC biomarker detection<\/p>\n

Wednesday, April 22 | 9AM\u201312PM PST\u200b | Poster Section 39\u200b
Poster<\/strong>: Blood-based proteomic profiling reveals novel biomarkers of Neuroendocrine Prostate Cancer\u200b<\/p>\n

Monday, April 20 | 2PM\u20135PM PST\u200b | Poster Section 44\u200b
Title<\/strong>: Performance validation of a next generation sequencing myeloid assay on an integrated nucleic acid purification and sequencing system\u200b<\/p>\n

\n
\n Molecular Residual Disease (MRD) Product Pipeline<\/u>
\n <\/strong>\n <\/p>\n

Another set of presentations highlights a novel, multi-omic approach to MRD monitoring. Thermo Fisher Scientific, Bio-Rad Laboratories, and Memorial Sloan Kettering Cancer Center will co-present new data on proteomic and genomic biomarkers as well as bioinformatics workflows central to the Biodesix MRD pipeline tests.<\/p>\n

Monday, April 20 | 12:30PM | Spotlight Theater B – Sails Pavilion – Conv Ctr
Title<\/strong>: Leveraging Droplet Digital PCR\u2122* (ddPCR\u2122) for MRD Detection and Monitoring in Solid Tumors and Heme Malignancies<\/p>\n

Tuesday, April 21 | 2PM\u20135PM PST\u200b | Poster Section 1\u200b
Poster<\/strong>: 5437. Sensitive detection of rare cfDNA variants utilizing molecular technologies and a novel informatics platform: A combined genomic and proteomic MRD application.\u200b<\/p>\n

\u200bWednesday, April 22 | 9AM\u201312PM PST\u200b | Poster Section 45\u200b
Poster:<\/strong> 7828. Development of a comprehensive tumor-informed ctDNA workflow for ultrasensitive molecular residual disease (MRD) detection using diverse tumor profiling inputs\u200b<\/p>\n

The full abstracts for Biodesix and a list of all abstracts being presented at the AACR Annual Meeting can be found here<\/a>.<\/p>\n